PT  - JOURNAL ARTICLE
AU  - Aruffo, Elena
AU  - Athar, Safia
AU  - Raad, Angie
AU  - Ali, Md Afsar
AU  - Althubyani, Mohammed
AU  - Chow, Christopher
AU  - Ruma, Mahmuda
AU  - Liu, Chao
AU  - Wu, Jianhong
AU  - Asgary, Ali
AU  - Kong, Jude D.
AU  - Heffernan, Jane M.
TI  - COVID-19 transmission in a theme-park
AID  - 10.1101/2021.04.15.21255560
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.15.21255560
4099  - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255560.short
4100  - http://medrxiv.org/content/early/2021/04/20/2021.04.15.21255560.full
AB  - Background As COVID-19 vaccination coverage increases, public health and industries are contemplating re-opening measures of public spaces, including theme-parks. To re-open, theme-parks must provide public health mitigation plans. Questions on implementation of public health mitigation strategies such as park cleaning, COVID-19 testing, and enforcement of social distancing and the wearing of personal protective equipment (PPE) in the park remain.Methods We have developed a mathematical model of COVID-19 transmission in a theme-park that considers direct human-human and indirect environment-human transmission of the virus. The model thus tracks the changing infection/disease landscape of all visitors, workers, and environmental reservoirs in a theme park setting.Findings Models results show that theme-park public health mitigation must include mechanisms that reduce virus contamination of the environment to ensure that workers and visitors are protected from COVID-19 transmission in the park. Thus, cleaning rates and mitigation of human-environment contact increases in importance.Conclusion Our findings have important practical implications in terms of public health as policy- and decision-makers are equipped with a mathematical tool that can guide theme-parks in developing public health mitigation strategies for a safe re-opening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by NSERC (JMH, JW, AA), an NSERC-Sanofi Industrial Research Chair (JW, JMH, AA), and the York University Research Chair program (JMH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:noneAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe source of data is cited in the manuscript.